These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1921 related articles for article (PubMed ID: 23964934)
1. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. Xie M; He CS; Huang JK; Lin QZ Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828 [TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. Escudier B; Porta C; Bono P; Powles T; Eisen T; Sternberg CN; Gschwend JE; De Giorgi U; Parikh O; Hawkins R; Sevin E; Négrier S; Khan S; Diaz J; Redhu S; Mehmud F; Cella D J Clin Oncol; 2014 May; 32(14):1412-8. PubMed ID: 24687826 [TBL] [Abstract][Full Text] [Related]
4. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Lai JS; Beaumont JL; Diaz J; Khan S; Cella D Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466 [TBL] [Abstract][Full Text] [Related]
5. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445 [TBL] [Abstract][Full Text] [Related]
6. Pazopanib outscores sunitinib on tolerability. Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960 [TBL] [Abstract][Full Text] [Related]
7. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31]. Trump D Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300 [TBL] [Abstract][Full Text] [Related]
9. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763 [TBL] [Abstract][Full Text] [Related]
10. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131 [TBL] [Abstract][Full Text] [Related]
12. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Kim JH; Park I; Lee JL Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136 [TBL] [Abstract][Full Text] [Related]
13. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108 [TBL] [Abstract][Full Text] [Related]
14. Benefits of pazopanib over sunitinib for renal cell carcinoma. Granovetter M Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821 [No Abstract] [Full Text] [Related]
15. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517 [TBL] [Abstract][Full Text] [Related]
16. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772 [TBL] [Abstract][Full Text] [Related]
18. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616 [TBL] [Abstract][Full Text] [Related]
19. First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. Schmidinger M; Wittes J Curr Opin Urol; 2015 Sep; 25(5):395-401. PubMed ID: 26148069 [TBL] [Abstract][Full Text] [Related]
20. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224 [No Abstract] [Full Text] [Related] [Next] [New Search]